MedTrace Logo

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00967057 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 470

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia.

PURPOSE: This partially randomized phase III trial is studying how well combination chemotherapy works in treating young patients with relapsed or refractory acute lymphoblastic leukemia.

Conditions

Interventions

DRUG

asparaginase

Given intramuscularly

DRUG

dexamethasone

Given orally

DRUG

idarubicin

Given IV

DRUG

methotrexate

Given intrathecally

DRUG

mitoxantrone hydrochloride

Given IV

DRUG

pegaspargase

Given intramuscularly

DRUG

vincristine sulfate

Given IV

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Vaskar Saha, MD · The Christie NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2010-01-31
Completion
2011-12-31

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967057 on ClinicalTrials.gov